POST Online Media Lite Edition


Trials for AstraZeneca's coronavirus treatment set to begin in UK

Christian Fernsby |
The UK will be the first country to begin clinical trials of a new coronavirus antibody treatment developed by drugs giant AstraZeneca PLC aimed at people with a weakened immune system who cannot be vaccinated.

A participant in Manchester will be the first in the world to receive the pharmaceutical company's new "antibody cocktail" as part of the trial to test whether it will prevent Covid-19 for up to year.

The clinical trial programme will recruit 5,000 participants, which includes 1,000 people from nine sites in the UK.

The aim of the trial is to evaluate the safety and effectiveness of a combination of two long-acting monoclonal antibodies man made proteins that act like natural human antibodies in the immune system.

What to read next

Biopsies during early treatment predict response to melanoma immunotherapy
Pig trial of AstraZeneca's coronavirus vaccine shows promise with two shots
Three-minute brain stimulation therapy effective for hard-to-treat depression